论文部分内容阅读
如今新辅助化疗已成为综合治疗恶性肿瘤的一个重要组成部分,具有广阔的应用前景。Wang等研究了新辅助化疗前后直肠癌患者血清中血管内皮生长因子(VEGF)及血管内皮生长因子-2(VEGF-2)水平的变化,并讨论了肿瘤进展规律与疗效和预后的关系,为直肠癌的新辅助化疗提供了新思路。Wang等采用酶联免疫吸附检测方法检测了45例直肠癌患者新辅助化疗前后血液中的VEGF和VEGF-2水平(试验组),并与45例正常人的水平进行对比(对照组)。结果发现,经过连续
Today, neoadjuvant chemotherapy has become an important part of the comprehensive treatment of malignant tumors, with broad application prospects. Wang et al. Studied the changes of serum VEGF and VEGF-2 levels in patients with rectal cancer before and after neoadjuvant chemotherapy and discussed the relationship between tumor progression and efficacy and prognosis. Neoadjuvant chemotherapy for rectal cancer offers a new way of thinking. Wang et al detected the levels of VEGF and VEGF-2 in 45 patients with rectal cancer before and after neoadjuvant chemotherapy by enzyme-linked immunosorbent assay (experimental group) and compared with 45 normal controls (control group). The results showed that after continuous